Nitric Oxide Innovations LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin
Phase 1
Terminated
- Conditions
- COVID-19
- Interventions
- Drug: Nitric Oxide lozenges, 30 mgDrug: Placebo
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Nitric Oxide Innovations LLC
- Target Recruit Count
- 524
- Registration Number
- NCT04601077
- Locations
- 🇺🇸
American Institute of Therapeutics, Lake Bluff, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath